NCEL
Price:
$2.55
Market Cap:
$1.15M
NewcelX Ltd., a biotechnology company, engages in developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company was founded in 2008 and is headquartered in Zurich, Switzerland.
Industry
Biotechnology
IPO Date
2025-10-24
Stock Exchange
NASDAQ
Ticker
NCEL
According to NewcelX Ltd.’s latest financial reports and current stock price. The company's current Current Ratio is 2.77. This represents a change of 89.64% compared to the average of 1.46 of the last 4 quarters.
The mean historical Current Ratio of NewcelX Ltd. over the last ten years is 1.31. The current 2.77 Current Ratio has changed 21.01% with respect to the historical average. Over the past ten years (40 quarters), NCEL's Current Ratio was at its highest in in the June 2021 quarter at 6.91. The Current Ratio was at its lowest in in the June 2017 quarter at 0.
Average
1.31
Median
1.26
Minimum
0.03
Maximum
2.75
Discovering the peaks and valleys of NewcelX Ltd. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 8.62%
Maximum Annual Current Ratio = 2.75
Minimum Annual Increase = -98.37%
Minimum Annual Current Ratio = 0.03
| Year | Current Ratio | Change |
|---|---|---|
| 2024 | 2.69 | 1.07% |
| 2023 | 0.23 | -91.64% |
| 2022 | 2.75 | 15.58% |
| 2021 | 2.38 | 8.62% |
| 2020 | 0.03 | -71.14% |
| 2019 | 0.09 | 153.38% |
| 2018 | 0.04 | -98.37% |
The current Current Ratio of NewcelX Ltd. (NCEL) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
1.89
5-year avg
1.62
10-year avg
1.31
NewcelX Ltd.’s Current Ratio is greater than Ocean Biomedical, Inc. (0.06), greater than IMAC Holdings, Inc. (0.02), greater than Prenetics Global Limited (1.51), less than Surrozen, Inc. (13.15), greater than CERo Therapeutics Holdings, Inc. (0.30), less than SAB Biotherapeutics, Inc. (10.50), greater than BriaCell Therapeutics Corp. (2.44), greater than Nuwellis, Inc. (2.04), greater than Celularity Inc. (0.16), less than Pasithea Therapeutics Corp. (4.02),
| Company | Current Ratio | Market cap |
|---|---|---|
| 0.06 | $652.49K | |
| 0.02 | $302.80K | |
| 1.51 | $271.19M | |
| 13.15 | $189.26M | |
| 0.30 | $60.27K | |
| 10.50 | $42.25M | |
| 2.44 | $20.16K | |
| 2.04 | $3.78M | |
| 0.16 | $30.48M | |
| 4.02 | $6.40M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like NewcelX Ltd. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like NewcelX Ltd. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Current Ratio?
How can you use the Current Ratio?
What is NewcelX Ltd.'s Current Ratio?
How is the Current Ratio calculated for NewcelX Ltd. (NCEL)?
What is the highest Current Ratio for NewcelX Ltd. (NCEL)?
What is the 3-year average Current Ratio for NewcelX Ltd. (NCEL)?
What is the 5-year average Current Ratio for NewcelX Ltd. (NCEL)?
How does the current Current Ratio for NewcelX Ltd. (NCEL) compare to its historical average?